SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sanofi India informs about disclosure

29 Nov 2023 Evaluate

With reference to its earlier communication dated 17 November 2023, informing about the filing of an application before the Hon’ble NCLT, Mumbai Bench, seeking rectification of an apparent error in the order dated 9 November 2022, by which order, the company was directed to convene meeting of its equity shareholders and unsecured creditors, to consider the scheme of arrangement (‘Order’). In this regard, Sanofi India has informed that the Hon’ble NCLT, Mumbai Bench vide order dated 24 November 2023 has rectified the error by fixing the appointed date of the scheme as to 1 June 2023. A copy of the order dated 24 November 2023 as uploaded on the website of the NCLT is enclosed. 

The above information is a part of company’s filings submitted to BSE.

Sanofi India Share Price

3587.20 8.65 (0.24%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×